Neoadjuvant-intensified treatment for rectal cancer: Time to change?

World Journal of Gastroenterology

Volumn 19, Issue 20, 2013, Pages 3052-3061

  Musio, Daniela ^a   De Felice, Francesca ^a   Bulzonetti, Nadia ^a   Guarnaccia, Roberta ^a   Caiazzo, Rossella ^a   Bangrazi, Caterina ^a   Raffetto, Nicola ^a   Tombolini, Vincenzo ^a  

^a POLICLINICO UMBERTO I   (Italy)

Author keywords

Fluorouracil; Intensified radiochemotherapy; Neoadjuvant treatment; Oxaliplatin; Rectal cancer

Indexed keywords

DEXAMETHASONE; FLUOROURACIL; ONDANSETRON; OXALIPLATIN;

ABDOMINAL PAIN; ACUTE HEART INFARCTION; ACUTE TOXICITY; ADHESION; ADJUVANT THERAPY; ADULT; AGED; ALLERGIC REACTION; ARTICLE; BONE MARROW; COLONOSCOPY; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; CONTINUOUS INFUSION; DEATH; DEEP VEIN THROMBOSIS; DESQUAMATION; DIARRHEA; DIGITAL RECTAL EXAMINATION; DRUG WITHDRAWAL; DYSURIA; ECHOGRAPHY; FATIGUE; FECES INCONTINENCE; FEMALE; FEVER; FISTULA; HEART PALPITATION; HEMATOLOGIC DISEASE; HUMAN; HUMAN TISSUE; INTESTINE OBSTRUCTION; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PARESTHESIA; PELVIS PAIN SYNDROME; PROCTITIS; PRURITUS; RADIATION DERMATITIS; RECTOSCOPY; RECTUM CANCER; SENSORY NEUROPATHY; SEXUAL DYSFUNCTION; THROMBOEMBOLISM; TUMOR VOLUME; URINARY FREQUENCY; URINE INCONTINENCE; UROGENITAL TRACT DISEASE; VOMITING;

EID: 84878230977     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i20.3052     Document Type: Article

References (33)

1. Marijnen CA, Nagtegaal ID, Klein Kranenbarg E, Hermans J, van de Velde CJ, Leer JW, van Krieken JH. No downstaging after short-term preoperative radiotherapy in rectal cancer patients. J Clin Oncol 2001; 19: 1976-1984 [PMID: 11283130]
2. Francois Y, Nemoz CJ, Baulieux J, Vignal J, Grandjean JP, Partensky C, Souquet JC, Adeleine P, Gerard JP. Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: the Lyon R90-01 randomized trial. J Clin Oncol 1999; 17: 2396 [PMID: 10561302]
3. Dolinsky CM, Mahmoud NN, Mick R, Sun W, Whittington RW, Solin LJ, Haller DG, Giantonio BJ, O'Dwyer PJ, Rosato EF, Fry RD, Metz JM. Effect of time interval between surgery and preoperative chemoradiotherapy with 5-fluorouracil or 5-fluorouracil and oxaliplatin on outcomes in rectal cancer. J Surg Oncol 2007; 96: 207-212 [PMID: 17443718 DOI: 10.1002/ jso.20815]
4. Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF, Karstens JH, Liersch T, Schmidberger H, Raab R. Preopera-tive versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004; 351: 1731-1740 [PMID: 15496622 DOI: 10.1056/NEJMoa040694]
5. André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I, de Gramont A. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350: 2343-2351 [PMID: 15175436]
6. Sanoff HK, Carpenter WR, Martin CF, Sargent DJ, Meyerhardt JA, Stürmer T, Fine JP, Weeks J, Niland J, Kahn KL, Schymura MJ, Schrag D. Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer. J Natl Cancer Inst 2012; 104: 211-227 [PMID: 22266473]
7. Hospers GA, Punt CJ, Tesselaar ME, Cats A, Havenga K, Leer JW, Marijnen CA, Jansen EP, Van Krieken HH, Wiggers T, Van de Velde CJ, Mulder NH. Preoperative chemoradiotherapy with capecitabine and oxaliplatin in locally advanced rectal cancer. A phase I-II multicenter study of the Dutch Colorectal Cancer Group. Ann Surg Oncol 2007; 14: 2773-2779 [PMID: 17653805]
8. Dionisi F, Musio D, Raffetto N, Codacci-Pisanelli G, Iannacone E, Caiazzo R, Banelli E. Preoperative intensified radiochemotherapy for rectal cancer: experience of a single institution. Int J Colorectal Dis 2011; 26: 153-164 [PMID: 21107849 DOI: 10.1007/s00384-010-1064-9]
9. Gherardi G, Bianchi F. Colon and rectum. In: Green FL, Compton CC, Fritz AG, Shah J, Winchester DP, editors. AJCC Cancer Staging Atlas. 6th ed. New York: Springer, 2007: 107-117
10. Cancer Therapy Evaluation Program (2006) Common Terminology Criteria for Adverse Events, Version 3.0. Available from: URL: http://ctep.cancer.gov
11. Valentini V, Lambin P, Myerson RJ. Is it time for tailored treatment of rectal cancer? From prescribing by consensus to prescribing by numbers. Radiother Oncol 2012; 102: 1-3 [PMID: 22178690 DOI: 10.1016/j.radonc.2011.12.001]
12. Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, Daban A, Bardet E, Beny A, Ollier JC. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006; 355: 1114-1123 [PMID: 16971718 DOI: 10.1056/NEJMoa060829]
13. Gérard JP, Conroy T, Bonnetain F, Bouché O, Chapet O, Closon-Dejardin MT, Untereiner M, Leduc B, Francois E, Maurel J, Seitz JF, Buecher B, Mackiewicz R, Ducreux M, Bedenne L. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 2006; 24: 4620-4625 [PMID: 17008704 DOI: 10.1200/JCO.2006.06.7629]
14. Havenga K, Grossmann I, DeRuiter M, Wiggers T. Definition of total mesorectal excision, including the perineal phase: technical considerations. Dig Dis 2007; 25: 44-50 [PMID: 17384507 DOI: 10.1159/000099169]
15. Bolognese A, Cardi M, Muttillo IA, Barbarosos A, Bocchetti T, Valabrega S. Total mesorectal excision for surgical treatment of rectal cancer. J Surg Oncol 2000; 74: 21-23 [PMID: 10861603 DOI: 10.1002/1096-9098(200005)74:]
16. Piso P, Dahlke MH, Mirena P, Schmidt U, Aselmann H, Schlitt HJ, Raab R, Klempnauer J. Total mesorectal excision for middle and lower rectal cancer: a single institution experience with 337 consecutive patients. J Surg Oncol 2004; 86: 115-121 [PMID: 15170648 DOI: 10.1002/jso.20062]
17. Aschele C, Cionini L, Lonardi S, Pinto C, Cordio S, Rosati G, Artale S, Tagliagambe A, Ambrosini G, Rosetti P, Bonetti A, Negru ME, Tronconi MC, Luppi G, Silvano G, Corsi DC, Bochicchio AM, Chiaulon G, Gallo M, Boni L. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol 2011; 29: 2773-2780 [PMID: 21606427 DOI: 10.1200/ JCO.2010.34.4911]
18. Gérard JP, Azria D, Gourgou-Bourgade S, Martel-Laffay I, Hennequin C, Etienne PL, Vendrely V, François E, de La Roche G, Bouché O, Mirabel X, Denis B, Mineur L, Berdah JF, Mahé MA, Bécouarn Y, Dupuis O, Lledo G, Montoto-Grillot C, Conroy T. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol 2010; 28: 1638-1644 [PMID: 20194850 DOI: 10.1200/JCO.2009.25.8376]
19. Fernández-Martos C, Pericay C, Aparicio J, Salud A, Safont M, Massuti B, Vera R, Escudero P, Maurel J, Marcuello E, Mengual JL, Saigi E, Estevan R, Mira M, Polo S, Hernandez A, Gallen M, Arias F, Serra J, Alonso V. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study. J Clin Oncol 2010; 28: 859-865 [PMID: 20065174 DOI: 10.1200/JCO.2009.25.8541]
20. Machiels JP, Duck L, Honhon B, Coster B, Coche JC, Scalliet P, Humblet Y, Aydin S, Kerger J, Remouchamps V, Canon JL, Van Maele P, Gilbeau L, Laurent S, Kirkove C, Octave-Prignot M, Baurain JF, Kartheuser A, Sempoux C. Phase II study of preoperative oxaliplatin, capecitabine and external beam radiotherapy in patients with rectal cancer: the RadiOxCape study. Ann Oncol 2005; 16: 1898-1905 [PMID: 16219623 DOI: 10.1093/annonc/mdi406]
21. Zhao L, Bai C, Shao Y, Guan M, Jia N, Xiao Y, Qiu H, Zhang F, Yang T, Zhong G, Chen S. A phase II study of neoadjuvant chemoradiotherapy with oxaliplatin and capecitabine for rectal cancer. Cancer Lett 2011; 310: 134-139 [PMID: 21782322 DOI: 10.1016/j.canlet.2011.06.026]
22. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 2000; 160: 809-815 [PMID: 10737280 DOI: 10.1001/archinte.160.6.761]
23. Ng M, Cunningham D, Norman AR. The frequency and pattern of cardiotoxicity observed with capecitabine used in conjunction with oxaliplatin in patients treated for advanced colorectal cancer (CRC). Eur J Cancer 2005; 41: 1542-1546 [PMID: 15978800 DOI: 10.1016/j.ejca.2005.03.027]
24. Chau I, Brown G, Cunningham D, Tait D, Wotherspoon A, Norman AR, Tebbutt N, Hill M, Ross PJ, Massey A, Oates J. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer. J Clin Oncol 2006; 24: 668-674 [PMID: 16446339 DOI: 10.1200/ JCO.2005.04.4875]
25. Chua YJ, Barbachano Y, Cunningham D, Oates JR, Brown G, Wotherspoon A, Tait D, Massey A, Tebbutt NC, Chau I. Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRIdefined poor-risk rectal cancer: a phase 2 trial. Lancet Oncol 2010; 11: 241-248 [PMID: 20106720 DOI: 10.1016/S1470-2045(09)70381-X]
26. Mezi S, Musio D, Orsi E, de Felice F, Verdinelli I, Morano F, Raffetto N, Tombolini V. Incidence of thromboembolic events in patients with locally advanced rectal cancer receiving neoadjuvant chemoradiotherapy. Acta Oncol 2013; 52: 187-190 [PMID: 22671575 DOI: 10.3109/0284186X.2012.68911 4]
27. Carlomagno C, Farella A, Bucci L, D'Armiento FP, Pesce G, Pepe S, Cannella L, Pacelli R, De Stefano A, Solla R, D' Armiento MR, De Placido S. Neo-adjuvant treatment of rectal cancer with capecitabine and oxaliplatin in combination with radiotherapy: a phase II study. Ann Oncol 2009; 20: 906-912 [PMID: 19155242 DOI: 10.1093/annonc/mdn719]
28. Ofner D, Devries AF, Schaberl-Moser R, Greil R, Rabl H, Tschmelitsch J, Zitt M, Kapp KS, Fastner G, Keil F, Eisterer W, Jäger R, Offner F, Gnant M, Thaler J. Preoperative oxaliplatin, capecitabine, and external beam radiotherapy in patients with newly diagnosed, primary operable, cTNxM0, low rectal cancer: a phase II study. Strahlenther Onkol 2011; 187: 100-107 [PMID: 21267531 DOI: 10.1007/s00066-010-2182-6]
29. Gosens MJ, Klaassen RA, Tan-Go I, Rutten HJ, Martijn H, van den Brule AJ, Nieuwenhuijzen GA, van Krieken JH, Nagtegaal ID. Circumferential margin involvement is the crucial prognostic factor after multimodality treatment in patients with locally advanced rectal carcinoma. Clin Cancer Res 2007; 13: 6617-6623 [PMID: 18006762 DOI: 10.1158/1078-0432. CCR-07-1197]
30. Créhange G, Bosset JF, Maingon P. [Preoperative radiochemotherapy for rectal cancer: forecasting the next steps through ongoing and forthcoming studies]. Cancer Radiother 2011; 15: 440-444 [PMID: 21802334]
31. Gaedcke J, Liersch T, Hess C, Becker H, Rödel C, Ghadimi BM. [Rectal cancer: current status of multimodal therapy--when and how?]. Zentralbl Chir 2011; 136: 334-342 [PMID: 21863511 DOI: 10.1055/s-0031-1271581]
32. Valentini V, van Stiphout RG, Lammering G, Gambacorta MA, Barba MC, Bebenek M, Bonnetain F, Bosset JF, Bujko K, Cionini L, Gerard JP, Rödel C, Sainato A, Sauer R, Minsky BD, Collette L, Lambin P. Nomograms for predicting local recurrence, distant metastases, and overall survival for patients with locally advanced rectal cancer on the basis of European randomized clinical trials. J Clin Oncol 2011; 29: 3163-3172 [PMID: 21747092 DOI: 10.1200/JCO.2010.33.1595]
33. Bujko K, Nowacki MP, Nasierowska-Guttmejer A, Michalski W, Bebenek M, Kryj M. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg 2006; 93: 1215-1223 [PMID: 16983741 DOI: 10.1002/bjs.5506]